Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Net Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Net Margin for 4 consecutive years, with 70.13% as the latest value for Q1 2025.

  • On a quarterly basis, Net Margin rose 335224.0% to 70.13% in Q1 2025 year-over-year; TTM through Sep 2025 was 22.59%, a 481514.0% increase, with the full-year FY2024 number at 1907.68%, up 420744.0% from a year prior.
  • Net Margin was 70.13% for Q1 2025 at Century Therapeutics, up from 843.59% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 70.13% in Q1 2025 to a low of 33627.27% in Q2 2023.
  • A 4-year average of 7502.51% and a median of 3545.65% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -3140750bps in 2023, then skyrocketed 2957967bps in 2024.
  • Century Therapeutics' Net Margin stood at 6080.04% in 2022, then plummeted by -142bps to 14700.75% in 2023, then surged by 94bps to 843.59% in 2024, then soared by 108bps to 70.13% in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Net Margin are 70.13% (Q1 2025), 843.59% (Q4 2024), and 3947.66% (Q3 2024).